ArticleJournal of thoracic disease2025

Grade-driven adjuvant chemotherapy benefit in high-risk stage IB NSCLC: a retrospective cohort study.

Heng Tao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.